Physician profile
Takugo Cho
NPI 1699527333
$1,437.53
in general payments reported to CMS, 2019-2025
18 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $619 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.98 | 2024-2025 | |
| Novo Nordisk INC | $156.82 | 2024-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $155.33 | 2024 | Entyvio |
| Abbott Laboratories | $102.10 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $96.05 | 2025 | Evenity |
| Regeneron Healthcare Solutions, INC. | $85.19 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $69.66 | 2025 | Rezdiffra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.86 | 2024-2025 | Lifevest |
| Fresenius Kabi USA, LLC | $46.77 | 2024-2025 | Idacio |
| Janssen Biotech, INC. | $41.82 | 2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $40.08 | 2025 | |
| Grifols USA, LLC | $32.37 | 2024 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $28.71 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.59 | 2025 | |
| Dexcom, INC. | $23.06 | 2025 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $18.33 | 2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $14.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Takugo Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.